ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition ...

Abbott reports fourth-quarter sales that miss analysts’ estimates.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

For the current quarter ending in March, Abbott expects its per-share earnings to range from $1.12 to $1.18. The company ...

Abbott Laboratories ( ABT) is scheduled to announce Q4 earnings results on Thursday, January 22nd, before market open. The ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter earnings that met expectations but missed on revenue, sending shares down 4.8% as investors reacted to the shortfall and weaker-than-expected ...

European shares were higher today. The eurozone's STOXX 600 gained 1.09%, while Spain's IBEX 35 Index rose 1.01%. London's FTSE 100 rose 0.26%, Germany's DAX gained 1.19% and France's CAC 40 gained ...